 |
|
UCLA cancer researchers first to link intestinal inflammation with systemic chromosome damage
June 01, 2009Discovery may lead to the early identification and treatment of inflammation, which increases cancer risk
UCLA scientists have linked for the first time intestinal inflammation with systemic chromosome damage in mice, a finding that may lead to the early identification and treatment of human inflammatory disorders, some of which increase risk for several types of cancer.
Researchers found that local intestinal inflammation induced DNA damage to lymphocytes of the peripheral blood circulating throughout the body. This means that chromosome damage was not limited to the intestine, but involved tissues of the body distant from the site of inflammation. The team found single- and double-strand DNA breaks in the blood, and chromosome damage in peripheral blood indicating systemic genetic damage.
Inflammatory diseases have been linked to some lymphomas and abdominal, liver and colorectal cancers, said Robert Schiestl, a professor of pathology, radiation oncology and environmental health sciences and a Jonsson Cancer Center scientist. If inflammation can be found early - before any symptoms arise - and the diseases treated immediately, it may prevent the damage that eventually leads to these cancers, he said.
The study appears in the June 1, 2009, edition of CANCER RESEARCH, the peer- reviewed journal for the American Association for Cancer Research.
"This was not known before, that intestinal inflammation causes damage that can be found throughout the body," said Schiestl, the study's senior author. "This may help explain how inflammation leads to these cancers."
Conditions that cause intestinal inflammation include Crohn's disease, inflammatory bowel disease, ulcerative colitis and Celiac disease. About 1.4 million people in the United States and 2.2 million Europeans currently suffer from inflammatory bowel diseases and incidence worldwide is increasing, Schiestl said.
The chromosome damage in the peripheral circulating blood could be used as a biomarker to identify those with intestinal inflammation before they show any symptoms or suffer any distress. In the study, the chromosome damage could be detected in the blood before the onset of colitis in the mouse models the team studied, which were engineered to develop the inflammatory disorder, said Aya Westbrook, a graduate student of the UCLA Molecular Toxicology Interdepartmental Program and first author of the paper. She also noted that the severity of the disease correlated with higher levels of chromosome damage in the blood.
Dr. Jonathan Braun, professor and chairman of the Department of Pathology and Laboratory Medicine at UCLA and a study author, said the chromosome damage may be the "earliest detectable indicator" of intestinal inflammatory diseases.
"Patients come to us with abdominal complaints and we can't tell if they are inflammatory, obstructive or a bacterial overgrowth," said Braun, who also is a researcher at UCLA's Jonsson Cancer Center. "At present, the only way to diagnose the patients is to do full endoscopic examinations, which are both invasive and expensive. "
In principle, Braun said, this biomarker blood test could replace the invasive endoscopic exam and allow physicians to identify smoldering inflammatory disease before it becomes full blown.
"This may give us the opportunity to ward off the disease early and avoid the subsequent organ damage," Braun said. "This could change the natural history of these diseases."
Treating these diseases early would not only bring patients relief, it could prevent the cancers that might have developed later, Braun said.
"We know that prolonged exposure to intestinal inflammatory disease leads to greatly increased risk of cancer," he said. "If we can reduce the inflammation, we may be able to prevent the cancer."
UCLA researchers have launched a clinical trial to confirm their findings in humans, Schiestl said. They're focusing on patients with Crohn's disease and ulcerative colitis.
"This discovery may give us an opportunity to test new strategies to treat smoldering disease, which we've never been able to identify before," Schiestl said. "We may be able to test new drugs to see which are best at treating early inflammatory disease."
The research also may uncover why some patients with inflammatory disease develop cancers, while others may have chronic inflammatory disorders for decades and never develop cancer. There may be molecular mechanisms at work that protect some patients and not others. If those mechanisms could be found, it could lead to tests that can predict which patients with intestinal inflammatory diseases are predisposed to cancer.
University of California - Los Angeles
Inflammatory diseases have been linked to some lymphomas and abdominal, liver and colorectal cancers, said Robert Schiestl, a professor of pathology, radiation oncology and environmental health sciences and a Jonsson Cancer Center scientist. If inflammation can be found early - before any symptoms arise - and the diseases treated immediately, it may prevent the damage that eventually leads to these cancers, he said.
The study appears in the June 1, 2009, edition of CANCER RESEARCH, the peer- reviewed journal for the American Association for Cancer Research.
"This was not known before, that intestinal inflammation causes damage that can be found throughout the body," said Schiestl, the study's senior author. "This may help explain how inflammation leads to these cancers."
Conditions that cause intestinal inflammation include Crohn's disease, inflammatory bowel disease, ulcerative colitis and Celiac disease. About 1.4 million people in the United States and 2.2 million Europeans currently suffer from inflammatory bowel diseases and incidence worldwide is increasing, Schiestl said.
The chromosome damage in the peripheral circulating blood could be used as a biomarker to identify those with intestinal inflammation before they show any symptoms or suffer any distress. In the study, the chromosome damage could be detected in the blood before the onset of colitis in the mouse models the team studied, which were engineered to develop the inflammatory disorder, said Aya Westbrook, a graduate student of the UCLA Molecular Toxicology Interdepartmental Program and first author of the paper. She also noted that the severity of the disease correlated with higher levels of chromosome damage in the blood.
Dr. Jonathan Braun, professor and chairman of the Department of Pathology and Laboratory Medicine at UCLA and a study author, said the chromosome damage may be the "earliest detectable indicator" of intestinal inflammatory diseases.
"Patients come to us with abdominal complaints and we can't tell if they are inflammatory, obstructive or a bacterial overgrowth," said Braun, who also is a researcher at UCLA's Jonsson Cancer Center. "At present, the only way to diagnose the patients is to do full endoscopic examinations, which are both invasive and expensive. "
In principle, Braun said, this biomarker blood test could replace the invasive endoscopic exam and allow physicians to identify smoldering inflammatory disease before it becomes full blown.
"This may give us the opportunity to ward off the disease early and avoid the subsequent organ damage," Braun said. "This could change the natural history of these diseases."
Treating these diseases early would not only bring patients relief, it could prevent the cancers that might have developed later, Braun said.
"We know that prolonged exposure to intestinal inflammatory disease leads to greatly increased risk of cancer," he said. "If we can reduce the inflammation, we may be able to prevent the cancer."
UCLA researchers have launched a clinical trial to confirm their findings in humans, Schiestl said. They're focusing on patients with Crohn's disease and ulcerative colitis.
"This discovery may give us an opportunity to test new strategies to treat smoldering disease, which we've never been able to identify before," Schiestl said. "We may be able to test new drugs to see which are best at treating early inflammatory disease."
The research also may uncover why some patients with inflammatory disease develop cancers, while others may have chronic inflammatory disorders for decades and never develop cancer. There may be molecular mechanisms at work that protect some patients and not others. If those mechanisms could be found, it could lead to tests that can predict which patients with intestinal inflammatory diseases are predisposed to cancer.
University of California - Los Angeles
Growing evidence of marijuana smoke's potential dangers
In a finding that challenges the increasingly popular belief that smoking marijuana is less harmful to health than smoking tobacco, researchers in Canada are reporting that smoking marijuana, like smoking tobacco, has toxic effects on cells.
Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold
New data from studies presented at the XVII International AIDS Conference in Mexico City have provided unprecedented insight into the toxicity of an impurity called ethyl methanesulfonate (EMS). The formation of the EMS impurity is a potential by-product of the manufacturing of mesylate salts, which are contained in over 40 drugs currently available worldwide.
Let's Stick Together - A Protein Protects Chromosome Bonds
The protein Mnd2 inhibits premature separation of chromosomes during the formation of gametes. The now published discovery of this regulatory function may help to understand the origin of some common congenital chromosome defects. The project of a team of the University of Vienna funded by the Austrian Science Fund (FWF) contributes to the Campus Vienna Biocenter maintaining a top-level position in the field of cell division research.
New research suggests early diet may play key role in protecting against childhood leukaemia
Incidence rates of childhood leukaemia are significantly lower in Asia than in Western countries and delegates at a conference in London (Thursday 9 September) will consider evidence that this may be due to differences in diet pattern.
Telomerase inhibition - a cancer therapy that is not always what it seems
Telomerase is a protein involved in cancer where it is present in 85 to 90% of all cases. Taking advantage of this fact, over the last years multiple new approaches have appeared that aim to inhibit telomerase activity as a new treatment strategy in human cancer. However, in the latest issue of the journal Oncogene scientists reveal that in some types of cancers anti-telomerase therapy, instead of kill cancerous cells puts them into senescence, a physiological state where cells although unable to divide and consequently grow, are nevertheless metabolically active. This would imply the need for expensive long-term treatment and, because cancerous cells are alive, the possibility that resista
More Chromosome Damage Current Events and Chromosome Damage News Articles
 |
Chromosome Damage (S/T) Chromosome Damage (Primary Contributor) |
![Assessment of DNA damage in nuclear medicine personnel - comparative study with the alkaline comet assay and the chromosome aberration test [An article ... Journal of Hygiene and Environmental Health]](http://ecx.images-amazon.com/images/I/51D8PA7D0TL._SL160_.jpg) |
Assessment of DNA damage in nuclear medicine personnel - comparative study with the alkaline comet assay and the chromosome aberration test [An article ... Journal of Hygiene and Environmental Health] by N. Kopjar (Author), V. Garaj-Vrhovac (Author) This digital document is a journal article from International Journal of Hygiene and Environmental Health, published by Elsevier in 2005. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Despite much research over the last few decades, there still remains considerable uncertainty as to the genetic impact of ionizing radiation on human populations, particularly at low levels. The aim of the present study was to provide data on the genetic hazards due to occupational exposure of low doses of ionizing radiation in nuclear medicine departments. The assessment of primary DNA damage in peripheral blood leukocytes of medical staff was performed using the alkaline... |
|
Chromosome Damage by Chromosome Damage | |
|
|
Abby's Cross Chromosome Damage (Primary Contributor) |
 |
Chromosome Damage By Environmental Agents by PR Reddy (Author) Many of the earliest books, particularly those dating back to the 1900s and before, are now extremely scarce and increasingly expensive. Hesperides Press are republishing these classic works in affordable, high quality, modern editions, using the original text and artwork. |
|
|
Spectral Assassin Chromosome Damage (Primary Contributor) |
|
Mutagen-Induced Chromosome Damage in Man by H. & Lloyd. D Evans (Author) | |
|
|
Stargazer Chromosome Damage (Primary Contributor) |
|
Mutagen-induced Chromosome Damage in Man by H. J. Evans (Editor), D. C. Lloyd (Editor) | |
|
|
Nemesis Chromosome Damage (Primary Contributor) |
| © 2009 BrightSurf.com |